<DOC>
	<DOC>NCT01406860</DOC>
	<brief_summary>The purpose of this study is to determine if droperidol is equally as effective as metoclopramide for treatment of primary headaches in the Emergency Department.</brief_summary>
	<brief_title>Droperidol Versus Metoclopramide for the Treatment of Primary Headaches</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Cluster Headache</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Metoclopramide</mesh_term>
	<mesh_term>Droperidol</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<criteria>18 years old to 65 years old, diagnosis of primary headache Allergy to study medications, pregnant, breastfeeding, prisoners, nonenglish speaking, not eligible to receive droperidol based on ED protocol (see below), patients in whom head trauma, infection, vascular disorders, and disorders of facial or cranial structures are suspected ED Droperidol Protocol Droperidol must NOT be used in patients with any of the following: Known or suspected QT prolongation, including congenital long QT syndrome Cardiac Disease [cardiomyopathy, congestive heart failure, hypertension, ischemic heart disease, myocardial infarction, bradycardia (&lt; 50 bpm)] History of the following: Renal failure Cerebrovascular disease Diabetes or hypoglycemia Alcoholism/alcohol abuse Pituitary insufficiency Hypothyroidism Hypothermia Anorexia Advanced age (&gt;65 yrs) Use of the following medications: digoxin, benzodiazepine, diuretics, IV opiates, or other medications known to prolong the QTc interval.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Headaches</keyword>
	<keyword>Migraines</keyword>
	<keyword>Tension headaches</keyword>
	<keyword>Cluster headaches</keyword>
</DOC>